乳腺癌内科治疗新进展—— 胡夕春PPT.ppt

乳腺癌内科治疗新进展;新药新方案 新理念 新药不良反应及处理 ;1.1白蛋白结合紫杉醇 (ABX) ;1.2 EFECT: Evaluation of Treatment Options Following AI Failure;EFECT: Similar TTP in Patients Treated With Fulvestrant or Exemestane;Ixabepilone+Capecitabine vs Capecitabine;Ixabepilone+Capecitabine vs Capecitabine;新药新方案 新理念 新药不良反应及处理 ;2.1;Treatment Efficacy: Lapatinib Vs Lapatinib + Trastuzumab;Progression-Free Survival: L Vs L+T;Geyer CE, et al. ASCO 2006. Clinical Science Symposium.;EGF100151: Lapatinib + Capecitabine in Advanced Breast Cancer (cont’d);Docetaxel + Avastin 15mg/kg every3 weeks;HR + 95% CI (unstratified);Miller et al. ASCO 2005. Oral presentation during symposium, Advances in Monoclonal Antibody Therapy for Breast Cancer. ;Miller et al. ASCO 2005. Oral presentation during symposium, Advances in Monoclonal Antibody Therapy for Breast Cancer. ; Xe 1000 mg/m2 BID PTX 175 mg/m2 (n = 431);Phase III study of Paclitaxel+Xeloda (XP) vs Paclitaxel+EPI (EP);2.3 NSABP B-33 ;Years After Surgery;2.4 TAnDEM 研究设计;Progression-free survival;2.5 HTX:HT Time to progression;新药新方案 新理念 新药不良反应及处理 ;3.1攻克血脑屏障的新手段 ;TransATAC central laboratory analysis indicates benefit of anastrozole over tamoxifen similar for ER-positive patients with or without being PR positive, according to central analysis All patients HR: 0.72 ER-positive/PR-positive patients HR: 0.72 ER-positive/PR-negative patients HR: 0.66;Benefit of anastrozole over tamoxifen better for patients with no HER2 expression, but confidence intervals of relative benefits with 2 treatments overlapped All patients HR: 0.72 HER2-negative patients HR: 0.66 HER2-positive patients HR: 0.92; 9,022 HR+ patients Recruitment period: 1987-2001 Latest follow-up: 2006 Median follow-up: 6.8 years Mean age: 43.6 years;Chemotherapy (± tam) ± LHRH (n=2741);3.4;3.5 基因芯片;FDA 批准;Oncotype DX;Predicting Tamoxifen Benefit With Recurrence Score (RS) Assay;Prognostic Value of Recurrence Score Assay;Prognostic Value of RS Assay in Tamoxifen-Treated Patients;辅助化疗瓶颈 ;Phase III t